Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Fey

Showing results (261-270 of 271) with videos related to

Pageof 28
Sort By:
Ejhaem|October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaStefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2007
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancerPer Karlsson, Bernard F Cole, Karen N Price, et al.
Bone Marrow Transplantation|July 22, 1999
Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?E Vellenga, W L van Putten, M A Boogaerts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experienceMarco Colleoni, David Zahrieh, Richard D Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 1997
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemiaB Löwenberg, M A Boogaerts, S M Daenen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2004
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experienceG Berclaz, S Li, K N Price, et al.
Lancet (London, England)|May 5, 2009
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trialsJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
The Cochrane Database of Systematic Reviews|July 10, 2009
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient dataJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
Leukemia|November 28, 2014
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 yearsJ J Cornelissen, J Versluis, J R Passweg, et al.
ESMO Open|November 16, 2016
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016Christian Dittrich, Michael Kosty, Svetlana Jezdic, et al.
Pageof 28

Showing results (261-270 of 271) with videos related to

Sort By:
Pageof 28
Ejhaem|October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaStefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2007
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancerPer Karlsson, Bernard F Cole, Karen N Price, et al.
Bone Marrow Transplantation|July 22, 1999
Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?E Vellenga, W L van Putten, M A Boogaerts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experienceMarco Colleoni, David Zahrieh, Richard D Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 1997
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemiaB Löwenberg, M A Boogaerts, S M Daenen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2004
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experienceG Berclaz, S Li, K N Price, et al.
Lancet (London, England)|May 5, 2009
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trialsJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
The Cochrane Database of Systematic Reviews|July 10, 2009
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient dataJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
Leukemia|November 28, 2014
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 yearsJ J Cornelissen, J Versluis, J R Passweg, et al.
ESMO Open|November 16, 2016
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016Christian Dittrich, Michael Kosty, Svetlana Jezdic, et al.
Pageof 28